Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission

Autologous Bone Marrow Transplantation for Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00186381

Enrollment

200

Registered

2005-09-16

Start date

1995-11-30

Completion date

2007-03-31

Last updated

2010-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood and Marrow Transplant (BMT), Leukemia, Leukemia, Myelocytic, Acute

Brief summary

Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.

Detailed description

To use high dose chemotherapy with autologous stem cell rescue to try to increase the chance of long term control and cure of the disease.

Interventions

PROCEDUREhigh dose chemotherapy then autologous hematopoietic cell transplant

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to 69 Years

Healthy volunteers

Inclusion criteria

- must be in remission * adequate organ function

Exclusion criteria

- prior MDS * active infection * liver disease

Design outcomes

Primary

Measure	Time frame
Disease free survival (DFS)	—

Secondary

Measure	Time frame
Transplant related mortality (TRM)	—
Toxicity	—
Adequacy of cell collections	—
Engraftment kinetics	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026